MedTrace Logo

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

NCT04729348 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-07-25

No results posted yet for this study

Summary

The purpose of this research is to examine if an experimental drug combination impacts the survival rate of individuals with Leptomeningeal Metastases

This research study involves an experimental drug combination.

The names of the study drugs involved in this study are:

* Pembrolizumab
* Lenvatinib

Conditions

  • Solid Tumor
  • Solid Tumor, Adult
  • Leptomeningeal Metastasis

Interventions

DRUG

Pembrolizumab

Oral, daily, dosage per protocol

DRUG

Lenvatinib

Oral, daily, dosage per protocol

Sponsors & Collaborators

Principal Investigators

  • Nancy Wang, MD, MPH · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2024-01-17
Completion
2024-01-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04729348 on ClinicalTrials.gov